Hansa Biopharma Partners With Cradle on AI Protein Design
Hansa Biopharma is partnering with Cradle to use AI for protein design and engineering across its drug discovery pipeline, the companies announced in a press release. The work will focus on therapeutic candidates for severe autoimmune diseases.
Hansa will use Cradle's platform for tasks including candidate identification, design and optimization. The system can optimize proteins across multiple parameters and learn from Hansa's experimental data to inform subsequent laboratory work.
The partnership expands Hansa's use of AI in research for immunomodulatory therapies. Cradle says its platform is used in more than 80 active research and development programs across pharmaceuticals, industrial biology, agriculture and consumer goods.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 19 MegaRobo raises nearly $200 million to let AI run real lab experiments Nov 18 AlphaFold screen maps nearly 2,900 likely interactions among human mitochondrial proteins Nov 18 Hone Health raises $228 million to expand AI-enabled longevity care Nov 18 Tesorai raises $5.3 million to make raw lab data searchable with AI Nov 18 nference and Novo Nordisk partner on AI research into obesity, diabetes and heart diseaseLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Genedata Adds NVIDIA RFD4-Proteina to Biologics Discovery Workflows
Isomorphic Labs raises $5 billion Series C for AI drug design
Anthropic Reports Early Claude Results in Drug Development
AstraZeneca and Oracle Partner on AI for Clinical Trials
Phylo Brings Biomni Lab AI Agents to Bayer
Daily AI Brief: the AI news that matters, in your inbox.